- Home
- BCAX vs CELC Comparison
BCAX vs CELC Comparison
Compare BCAX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- CELC
- Stock Information
- Founded
- BCAX 2018
- CELC 2011
- Country
- BCAX United States
- CELC United States
- Employees
- BCAX N/A
- CELC N/A
- Industry
- BCAX
- CELC Medical Specialities
- Sector
- BCAX
- CELC Health Care
- Exchange
- BCAX NYSE
- CELC Nasdaq
- Market Cap
- BCAX 541.0M
- CELC 440.0M
- IPO Year
- BCAX 2024
- CELC 2017
- Fundamental
- Price
- BCAX $10.53
- CELC $39.91
- Analyst Decision
- BCAX Strong Buy
- CELC Strong Buy
- Analyst Count
- BCAX 7
- CELC 6
- Target Price
- BCAX $29.17
- CELC $39.67
- AVG Volume (30 Days)
- BCAX 329.8K
- CELC 2.4M
- Earning Date
- BCAX 08-16-2025
- CELC 08-13-2025
- Dividend Yield
- BCAX N/A
- CELC N/A
- EPS Growth
- BCAX N/A
- CELC N/A
- EPS
- BCAX N/A
- CELC N/A
- Revenue
- BCAX N/A
- CELC N/A
- Revenue This Year
- BCAX N/A
- CELC N/A
- Revenue Next Year
- BCAX N/A
- CELC N/A
- P/E Ratio
- BCAX N/A
- CELC N/A
- Revenue Growth
- BCAX N/A
- CELC N/A
- 52 Week Low
- BCAX $7.80
- CELC $7.58
- 52 Week High
- BCAX $28.09
- CELC $46.42
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- CELC 91.78
- Support Level
- BCAX N/A
- CELC $34.30
- Resistance Level
- BCAX N/A
- CELC $46.42
- Average True Range (ATR)
- BCAX 0.00
- CELC 2.40
- MACD
- BCAX 0.00
- CELC 2.96
- Stochastic Oscillator
- BCAX 0.00
- CELC 80.31
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.